KeyBanc raised the firm’s price target on Bio-Techne (TECH) to $90 from $80 and keeps an Overweight rating on the shares. Overall, fiscal Q2 represented a continuation of last quarter’s strength for Bio-Techne, and the firm believes it is a positive indicator for other life science tools companies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: